Abstract: An enantioselective synthesis of acyclic β-diaryl ketones and esters via 1,4-addition of arylboronic acids to β-aryl-α,β-unsaturated ketones or esters is described. The complex in situ prepared from [Rh(nbd) 2 ]BF 4 and chiraphos was found to be an excellent catalyst to achieve high enantioselectivities in a range of 83-89%ee for the ketone derivatives and 78-94%ee for t-butyl β-arylacrylate derivatives. The protocol provided a catalytic method for the enantioselective synthesis of selective endothelin A receptor antagonists (7, 8) reported by SmithKline Beecham and Merck-Banyu. The enantioselection 2 mechanism and efficiency of the chiraphos ligand for β-aryl-α,β-unsaturated ketones and esters are discussed on the basis of results of DFT computational studies on the modes of coordination of the enone substrates to the phenylrhodium(I)/(S,S)-chiraphos complex.
Introduction
1,4-Additions of electrophiles to α,β-unsaturated carbonyl compounds are a versatile methodology for forming carbon-carbon bonds.
1 Among these extensive studies in conjugate additions, we have disclosed the rhodium-catalyzed reaction of aryl-and 1-alkenylboronic acids. 2 Since the reaction yields a stereogenic center at the β-carbon, considerable efforts have been devoted to the development of asymmetric syntheses via metal-catalyzed 1,4-addition of organoboron, 3 -silicon, 4 -magnesium, 5 -zinc, 6 -tin, 7 -bismuth, 8 -titanium 9 and -indium 10 compounds to cyclic and acyclic α,β-unsaturated ketones, 3 esters, 3 amides, 11 phosphonates, 12 and nitro 13 compounds. A rhodium(I)-binap catalyst was the first catalyst to be successfully used in enantioselective 1,4-addition of aryl-and 1-alkenylboronic acids to cyclic and acyclic enones. 3a Other ligands effective for rhodium(I) catalysts are bisphosphine ligands of chiraphos 14 and diphosphonites, 3e P-N ligands of amidomonophosphines, 15 bis(alkene) ligands based on a norbornadiene skeleton, 16 and monophosphine ligands of 5 <<Table 1>>
1,4-Additions of representative arylboronic acids to β-aryl-α,β-unsaturated ketones and t-butyl esters with a rhodium(I)/(S,S)-chiraphos catalyst are shown in Table 2 . All additions to ketones were completed within 5 h at room temperature with enantioselectivities in a range of 83-89%ee (entries 1-5). Additions to t-butyl esters were carried out at 50 or 80 ˚C, but these reactions resulted in 5-10% higher enantioselectivities than those of ketone series (entries 6-16).
Substituents on arylboronic acids (FG in 2) and β-substituents of carbonyl compounds (Ar in 1) affected the enantioselectivities, suggesting their participation in enantioselection as is discussed in the mechanistic section. Substituents of arylboronic acids increased the selectivities in the order of 3,4-methylenedioxy (entries 2 and 9) > 4-methoxy (entries 1 and 6) > 3-methoxy (entry 7) > 3,4-dimethoxy (entry 8) >> 4-dimethylamino (entry 10). In additions of 3-methoxyphenylboronic acid to a series of β-arylacrylates, the selectivities of 4-methoxyphenyl, 4-methylphenyl and 2-methoxyphenyl derivatives were comparable to that of the phenyl group (entries 7 and 11-13), but 4-trifluoromethylphenyl and 2-naphthyl derivatives resulted in significantly lower enantioselectivities presumably due to steric reason (entries 14 and 15) . Although the pyridine nitrogen often retards metal-catalyzed reactions due to its strong ability to coordinate to most metal catalysts, it was interesting that arylboronic acids underwent very smooth addition to t-butyl 3-pyridylacrylate under standard conditions (entry 16). The absolute configurations of most products were not known, but the formation of S-product from (S,S)-chiraphos complex was established by the specific rotation reported for (S)-3-(3-methoxyphenyl)-1,3-diphenylpropan-1-one ([α] D +7.1 (c 0.71, CHCl 3 )) 20 (entry 4). <<Table 2>> 6
Synthesis of endothelin receptor antagonists
Much effort has been made by many research groups to prepare selective antagonists of endothelin receptors, which are currently being evaluated as potential therapeutic agents for the treatment of hypertension, congestive heart failure and renal diseases. 1,3-Diarylindan-2-caraboxylic acid derivatives are highly potent antagonists selective for endothelin receptors among non-peptide antagonists reported by Shionogi, 26 Hoffmann-La Roche, 27 Bristol-Myers Squibb, 28 SmithKline Beecham (6, 7), 29 and Merck-Banyu (8) . 30 Two general and flexible methods for the synthesis such a fused five-membered ring with three contiguous chiral centers have recently been accomplished by SmithKline Beecham 31 and Merck-Banyu. 30 In these approach, the major challenge of Merck-Banyu's group was enantioselective 1,4-addition of arylmetal reagents to β-aryl-α,β-unsaturated esters to build a five-membered ring and three chiral centers based on the first stereogenic center. Although they achieved excellent enantioselectivities by using a stoichiometric chiral auxiliary for 1,4-addition of aryllithium reagents, the catalytic protocol is preferred in large-scale preparations of these antagonists <<Figure 1>>
SmithKline Beecham's antagonist (7)
Most rhodium(I)-catalysts previously reported for 1,4-addition of arylboronic acids achieved significantly higher enantioselectivity for cyclic enones and 7 esters than those for acyclic derivatives. Thus, addition to benzo-fused 2-cyclopentenone 9 was the first choice for the synthesis of endothelin receptor antagonists (6 and 7) reported by SmithKline Beecham (Scheme 2). However, the substrate 9 was unfortunately very labile as neat or even in solutions. Thus, all attempts at using 9 as the starting compound failed. [Rh(nbd) 2 ]BF 4 -chiraphos (3a) resulted in 27% yield and 8%ee.
<<Scheme 2>>
An alternative approach for the synthesis of 7 from arylboronic acids and acyclic unsaturated esters is shown in Scheme 3. An aryl moiety 14 desired for introduction of the top functionality of 7 via palladium-catalyzed cross-coupling was obtained from readily available 4-bromoresorcinol (11). Chemoselective protection of the 4-hydroxy group of 11 with tosyl chloride was directly followed by treatment with ClCH 2 CH 2 OMOM. Deprotection and methylation of 12 furnished 13 in 75% total yield. A sequential treatment of 13 with magnesium turning and B(OMe) 3 gave the desired boronic acid 14 in 73% yield.
<<Scheme 3>>
The α,β-unsaturated ester (17) desired as a substrate for enantioselective 1,4-addition was synthesized by Heck coupling of 2-bromo-5-propoxybenzaldehyde (16), which was obtained from 2-bromo-5-hydroxybenzaldehyde (15) 31 . The enantiomer thus obtained was produced by the same mode of face selection as that discussed in the later section.
<<Scheme 4>>
The chiral diester 19 thus obtained was led to the target antagonist 7 by a method similar to that previously reported by SmithKline Beecham. Thus, the enolate resulting from 19 with NaH was sulfonylated with trifluoromethanesufonic anhydride to yield the triflate 20 in 72% yield (89%ee). Cross-coupling of 20 with 14 in the presence of PdCl 2 (dppf) and K 2 CO 3 to give 21 in 90% yield was followed by olefin reduction with H 2 and a palladium catalyst to give 22 in 90% yield. Finally, epimerization of the t-butyl ester group in 22 was followed by deprotection of t-butyl ester and MOM group to furnish 7.
31
The strategy thus achieved by asymmetric 1,4-addition and cross-coupling reaction of arylboronic acids has a structural flexibility for both top and bottom aryl groups for parallel synthesis of candidates.
Merck-Banyu's antagonists
For the synthesis of Merck-Banyu's antagonist 8, an unsaturated ester (27) was chosen as a substrate for the enantioselective addition of arylboronic acids to introduce the chiral stereogenic center, which was previously achieved by 1,4-addition of aryllithiums to unsaturated esters possessing an chiral auxiliary 9 (Scheme 5). The ester 27 was obtained in a high yield by the reported procedures starting from 2,6-dichloropyridine (24) . 32 With the substrate 27 in hand, the key asymmetric step was then investigated. The optimal conditions shown in Table 1 worked well for variously functionalized arylboronic acids with selectivities in a range of 90-95%ee, thus allowing the parallel synthesis of chiral β-aryl ester derivatives (28a-e). It was interesting that neither the substituents on the pyridyl ring nor the two nitrogens of 27 significantly affected the yields or enantioselectivities. They were comparable or even higher than those of unsaturated esters shown in Table 2 . The absolute configurations of 28e thus obtained by the (R,R)-chiraphos complex was established to be S by the specific rotation reported for (S)-28e. 33 Thus, the product was produced by the same mode of face selection same as that discussed in the later section ( Figure 3 ). In five steps, 28e completes a formal synthesis of one of Merck-Banyu's antagonists (8) . There is a precedent for the X-ray structure of a rhodium(I)-chiraphos complex; however, the solid-state structure of such a conformationally flexible complex, in general, is not reliable for the mechanism of enantioselection since the intermediate conformation differs from the structure of the catalyst precursor. Thus, the mode of a coordination of (E)-4-phenyl-3-buten- 46.0, 55.1 55.4, 111.2, 113.7, 114.0, 120.2, 126.3, 127.8, 128.5, 129.5, 130.3, 144.1, 145.9, 159.6, 163.4, 196.4; MS (m/z) 41.9, 47.3, 54.9, 80.3, 111.4, 113.7, 120.0, 126.3, 127.6, 128.3, 129.3, 143.3, 145.1, 159.5, 170.9; MS (m/z) 80. 2, 110.9, 111.1, 119.3, 126.2, 127.4, 128.2, 136.0, 143.6, 147.4, 148.6, 170.8; MS (m/z) 8, 42.1, 47.0, 80.4, 100.8, 108.0, 108.2, 120.5, 126.4, 127.5, 128.4, 137.5, 143.6, 146.0, 147.6, 170.9; MS (m/z) 6H), 4.31 (t, J = 8.3 Hz, 1H), 1H), 4H) , 7.04-7.09 (m, 3H); 13 C NMR (100 MHz, CDCl 3 ): δ 27.7, 42.1, 46.5, 54.9, 55.0, 80.3, 111.3, 113.6, 113.7, 119.9, 128.5, 129.3, 135.5, 145.5, 158.0, 159.5, 171.0 27.7, 40.4, 40.8, 54.9, 55.2, 80.0, 110.5, 111.1, 113.9, 120.2, 120.3, 127.4, 127.7, 128.9, 131.7, 144.9, 156.7, 159. 20.9, 27.8, 42.0, 46.9, 55.0, 80.3, 111.4, 113.7, 120.0, 127.5, 129.0, 129.3, 135.8, 140.4, 145.4, 159.5, 171.0; MS (m/z) 41.5, 47.1, 55.0, 80.7, 111.7, 113.8, 119.9, 122.8, 125.3, 125.3, 128.0, 129.6, 144.2, 147.5, 159.7, 170.5 8, 41.8, 47.3, 55.0, 80.4, 111.5, 113.9, 120.2, 125.4, 125.6, 125.9, 126.5, 127.5, 127.7, 128.1, 129.4, 132.2, 133.3, 140.8, 145.0, 159.6, 171.0; MS (m/z) 27.8, 41.5, 44.9, 55.1, 80.9, 111.8, 113.7, 119.9, 123.3, 129.6, 135.0, 138.8, 143.9, 147.9, 149.3, 159.7, 170.4; MS (m/z) 7, 149.4, 145.6, 133.3, 131.9, 129.8, 128.5, 115.4, 110.4, 108.1, 96.5, 68.8, 65.3, 55.3, 21.7; IR (neat) 2938 IR (neat) , 2885 IR (neat) , 1594 IR (neat) , 1477 IR (neat) , 1372 IR (neat) , 1273 IR (neat) , 1191 IR (neat) , 1179 IR (neat) , 1143 IR (neat) , 1117 IR (neat) , 1036 and water (30 mL) was heated under reflux for 2 h. The solvent was evaporated to reduce the volume. 4 M HCl was added at room temperature until pH 4. The product (13) 163.4, 138.0, 105.8, 99.1, 96.5, 67.5, 65.7, 55.4, 55.3; anal. calcd for C 11 H 17 BO 6 : C, 51.60%; H, 6.69%. Found: C, 51.45%; H, 6.62%. 
1-Bromo-4-methoxy-2-(2-methoxymethoxyethoxy)benzene (13

2-(2-tert-Butoxycarbonylvinyl)-5-propoxybenzoic acid methyl ester (17).
A solution of 2-bromo-5-hydroxybenzaldehyde (15) 40b (6 g, 30.0 mmol), 1-bromopropane (4.5 mL, 50.0 mmol) and K 2 CO 3 (6.6 g, 48.0 mmol) in EtOH (60 mL) and water (20 mL) was heated under reflux for 17 h. The solvent was then evaporated and the residue was filtrated through silica gel pad with hexane/EtOAc (1:1). The combined filtrate was concentrated to dryness.
The crude product was dissolved in acetone (56 mL) and water (18 mL), and slowly treated with KMnO 4 (9.5 g, 60.0 mmol) with stirring on a water bath.
After being stirred for 30 min, it was heated for 1 h at 70 °C. The reaction mixture was passed through Celite 545, rinsed with acetone, and then concentrated to a small volume. The reaction mixture was extracted with AcOEt and the organic layer was washed with dil. HCl. The organic layer was dried over MgSO 4
and, finally, concentrated to dryness.
The crude product was dissolved in MeOH (100 mL) and H 2 SO 4 (2 mL), and heated under reflux for 6 h using Dean-Stark apparatus. The solution was concentrated to a small volume and extracted with Et 2 O. The organic layer was washed successively with brine and water. The organic layer was dried over MgSO 4 and concentrated to dryness to give crude 16 (6.3 g).
A solution of the crude 16, PdCl 2 (MeCN) 2 (204 mg, 0.79 mmol), P(o-tol) 3 (458 mg, 1.50 mmol) and tert-butyl acrylate (3.6 mL, 24.9 mmol) in DMF (23 mL) and Et 3 N (7.6 mL) was stirred at 100 °C for 10 h. The product (17) 147.7, 146.7, 138.3, 135.5, 130.7, 130.5, 125.3, 121.3, 119 (q, J = 320 Hz), 117,1, 108.3, 107.5, 105.2, 100.9, 82.5, 69.8, 52.5, 27.8, 22.4, 10.4; IR (neat) 2966 IR (neat) , 1702 IR (neat) , 1490 IR (neat) , 1423 IR (neat) , 1337 IR (neat) , 1249 IR (neat) , 1202 IR (neat) , 1124 IR (neat) , 1040 6, 160.74, 160.70, 158.7, 156.9, 149.2, 147.5, 147.4, 146.1, 146.0, 145.0, 141.0, 140.8, 139.6, 139.2, 133.8, 133.5, 130.9, 23 130. 8, 124.3, 124.2, 121.28, 121.25, 117.0, 116.4, 114.6, 114.4, 108.4, 108.2, 108.1 108.0, 107.7, 107.4, 104.6, 100.7, 100.6, 99.8, 99.7, 96.49, 96.46, 79.8, 79.7, 69.6, 67.8, 67.6, 65.9, 65.7, 55.37, 55.33, 55.2, 54.9, 27.9, 27.8, 22.5, 10.5 ; IR (neat) 2932 IR (neat) , 1694 IR (neat) , 1595 IR (neat) , 1578 IR (neat) , 1502 IR (neat) , 1484 IR (neat) , 1440 IR (neat) , 1352 IR (neat) , 1242 IR (neat) , 1220 IR (neat) , 1151 IR (neat) , 1111 IR (neat) , 1035 2, 159.5, 158.4, 158.1, 147.0, 146.1, 145.7, 136.1, 133.3, 130.9, 125.2, 123.0, 119.8, 112.9, 111.2, 110.4, 107.6, 104.0, 100.7, 98.9, 96.5, 79.2, 69.7, 67.7, 66.0, 58.8, 55.3, 55.2, 52.3, 46.0, 27.4, 22.6, 10.5; IR (neat) 2933 IR (neat) , 1727 IR (neat) , 1609 IR (neat) , 1488 IR (neat) , 1441 IR (neat) , 1366 IR (neat) , 1283 IR (neat) , 1248 IR (neat) , 1229 IR (neat) , 1198 IR (neat) , 1145 IR (neat) , 1113 IR (neat) , 1036 4, 158.3, 150.3, 138.9, 138.4, 136.6, 128.7, 127.0, 126.2, 117.6, 116.2, 106.1, 80.3, 46.9, 46.5, 28.2, 20.2; IR (KBr) 2975 , 1702 , 1601 , 1532 , 1485 , 1363 , 1140 
(-)-(S)-2-(1-Benzo[1,3]dioxol-5-yl-2-tert-butoxycarbonylethyl)-5-propoxy-benzoic acid methyl ester (18).
1-Benzo[1,3]dioxol-5-yl-5-propoxy-3-trifluoromethanesulfonyloxy-1H-indene-2-carboxylic acid tert-butyl ester (20).
1-Benzo[1,3]dioxol-5-yl-3-[4-methoxy-2-(2-methoxymethoxyethoxy)phenyl]-5 -propoxy-1H-indene-2-carboxylic acid tert-butyl ester (21)
.
6-(N-Benzyl-N-isopropylamino)-3-(2-tert-butoxycarbonylvinyl)pyridine-2-carboxylic acid butyl ester (27):
To the vessel were added 26 (5 g, 12.9 25 mmol), AcONa•3H 2 O (2.6 g, 19.1 mmol), toluene (19 mL), and n-BuOH (38 mL). The mixture was degassed three times by vacuum/N 2 cycle. Pd(OAc) 2 (145 mg, 5 mol%) and DPPF (536 mg, 7.5 mol%) were then added, and the vessel was again degassed twice. The mixture was stirred at 120 °C for 16 h. After the completion of the reaction was confirmed by HPLC, the vessel was cooled to ambient temperature. The insoluble material was filtered through Celite and rinsed with EtOAc. The product was isolated by column chromatography (n-heptane/EtOAc = 20/1 to 10/1) to give 27 as oil. The oil was dissolved in EtOAc 8, 166.3, 158.0, 148.3, 139.1, 138.8, 135.7, 128.6, 126.9, 126.3, 118.3, 117.8, 109.3, 80.1, 65.5, 46.7, 46.6, 30.7, 28.3, 28.2, 20.2, 19.2, 13.7; IR (neat) 2972 IR (neat) , 1712 IR (neat) , 1597 IR (neat) , 1547 IR (neat) , 1484 IR (neat) , 1143 IR (neat) , 1075 
Rh-catalyzed asymmetric addition to 27:
To a round-bottom-flask was added 1,4-dioxane (2.0 mL) and water (0.5 mL), and the flask was then degassed three times by vacuum/N 2 cycle. To this solution was added [Rh(nbd) 2 ]BF 4 (3.0 mol%) and (R,R)-chiraphos (3.3 mol%) and the flask was gain degassed twice. After the mixture was aged for 15 min at ambient temperature, unsaturated ester (27, 0.4 mmol) in 1,4-dioxane (1.0 mL), KOH (0.8 mmol), 26 and arylboronic acid (1.2 mmol) were added. The flask was degassed twice. The mixture was heated to 50 °C for 14 h with vigorous stirring. The product was purified by column chromatography on silica gel.
The following compounds were synthesized by the above general procedure. 8, 167.6, 156.2, 146.4, 143.1, 139.8, 137.5, 128.4, 128.3, 127.8, 127.6, 126.6, 126.3, 125.7, 109.3, 80.4, 65.1, 46.6, 46.2, 42.0, 41.0, 30.6, 27.9, 27.8, 20.2, 20.1, 19.2, 13.7 5.04 (sept, J = 6.7 Hz, 1H), 4.89 (t, J = 8.3 Hz, 1H), 4.48 (s, 2H), 2H), 3.74 (s, 3H), 2.83 (d, J = 8.3 Hz, 2H), 1.72 (m, 2H), 2H 8, 167.6, 158.0, 156.2, 146.4, 139.8, 137.4, 135.3, 128.7, 128.4, 126.6, 126.3, 126.0, 113.7, 109.3, 80.4, 65.0, 55.2, 46.6, 46.2, 42.1, 40.3, 30.6, 27.9, 27.8, 20.2, 20.1, 19.2, 13.7; IR (KBr) 2972 , 1730 , 1600 , 1553 , 1481 , 1146 , 1077 , 1037 3, 167.3, 156.4, 146.3, 139.5, 137.2, 133.2, 128.5, 126.7, 126.3, 124.7, 116.1, 115.9, 109.5, 80.8, 65.2, 46.7, 46.3, 41.5, 40.3, 30.6, 27.8, 20.1, 19.2, 13. 
tert-Butyl-(3S)-3-[6-(N-benzyl-N-isopropylamino)-2-butoxycarbonyl-3-pyridinyl]-3-phenylpropanoate (28a
tert-Butyl-(3S)-3-[6-(N-benzyl-N-isopropylamino)-2-butoxycarbonyl-3-pyridinyl]-3-(4-methoxyphenyl)propanoate (28b
tert-Butyl-(3S)-3-[6-(N-benzyl-N-isopropylamino)-2-butoxycarbonyl-3-pyridinyl]-3-(3,4-methylenedioxyphenyl)propanoate (28d). 91% yield; R f
28
= 0.52 (n-heptane/ethyl acetate=2/1); 89.8 %ee (Chiralcel OD-H, n-hexane/2-propanol=90/10, flow rate=0.5 mL/min, temp=27 °C, t R for 28d: 10.0 min, 7, 167.6, 156.2, 147.6, 146.4, 145.9, 139.7, 137.3, 137.2, 128.4, 126.6, 126.3, 125.7, 120.5, 109.3, 108.6, 107.9, 100.8, 80.5, 65.1, 46.6, 46.2, 42.1, 40.7, 30.7, 27.9, 20.2, 20.1, 19.2, 13.7; IR (KBr) 8, 167.5, 160.3, 156.2, 146.4, 143.7, 139.8, 137.4, 128.4, 126.6, 126.3, 125.8, 124.8, 124.5, 120.0, 109.3, 108.7, 80.4, 71.2, 65.0, 46.6, 46.2, 42.0, 40.8, 30.7, 29.5, 27.9, 20.2, 20.1, 19.2, 13.7; IR (KBr) 2975 , 1730 , 1599 , 1481 , 1147 , 1078 
tert-Butyl-(3S)-3-[6-(N-benzyl-N-isopropylamino)-2-butoxycarbonyl-3-pyridinyl]-3-(2,3-dihydro-1-benzofuran-6-yl)propanoate (28e
Computational details.
Geometries of all stationary points were optimized using analytical energy gradients of self-consistent-field 41 and density functional theory (DFT). 42 The latter utilized Becke's three-parameter exchange-correlation functional 43 including the nonlocal gradient corrections described by Lee-Yang-Parr (LYP), 44 as implemented in the Gaussian 03 program package. 45 All geometry optimizations were performed using the LANL2DZ basis set. 
